Raymond James & Associates’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-9,894
| Closed | -$204K | – | 3795 |
|
|
2023
Q3 | $204K | Sell |
9,894
-137
| -1% | -$2.83K | ﹤0.01% | 3419 |
|
|
2023
Q2 | $296K | Sell |
10,031
-1,376
| -12% | -$40.6K | ﹤0.01% | 3240 |
|
|
2023
Q1 | $263K | Buy |
11,407
+1,490
| +15% | +$34.3K | ﹤0.01% | 3294 |
|
|
2022
Q4 | $276K | Buy |
+9,917
| New | +$276K | ﹤0.01% | 3251 |
|
|
2022
Q1 | – | Sell |
-4,926
| Closed | -$220K | – | 3969 |
|
|
2021
Q4 | $220K | Sell |
4,926
-1,245
| -20% | -$55.6K | ﹤0.01% | 3612 |
|
|
2021
Q3 | $311K | Sell |
6,171
-218
| -3% | -$11K | ﹤0.01% | 3363 |
|
|
2021
Q2 | $501K | Sell |
6,389
-1,096
| -15% | -$85.9K | ﹤0.01% | 3072 |
|
|
2021
Q1 | $427K | Sell |
7,485
-47
| -0.6% | -$2.68K | ﹤0.01% | 3111 |
|
|
2020
Q4 | $631K | Buy |
+7,532
| New | +$631K | ﹤0.01% | 2642 |
|